



**August 28th 2020 | CannPal Animal Therapeutics Limited | ASX: CP1
ASX ANNOUNCEMENT**

Resignation of Non-Executive Director

August 28th 2020: Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** (“CannPal” or “the Company”) today announces that Mr Max Johnston has tendered his resignation from the CannPal Board, effective September 3rd 2020.

Mr Johnston has been a non-executive director of CannPal since 2017, and due to increased workload in his capacity as a Non-Executive Director and/or Chairman for a number of other ASX listed Companies, compounded by the extended period of lockdown due to COVID-19, has made the decision to resign from the CannPal Board.

The Company thanks him for his many years of service and contribution. The Company does not intend on appointing a Director to replace Mr Johnston at this time.

CannPal Chairman, Mr Geoff Starr

“Max has been an instrumental part of CannPals growth in the previous 4 years, and on behalf of the Board I sincerely thank him for his support, guidance and invaluable expertise. I wish him and his family all the very best for the future.”

Mr Max Johnston

“My Confidence in CannPal remains extremely strong and I feel the work already undertaken has laid a good foundation for its future success. I particularly acknowledge management in delivering sector leading studies whilst remaining lean and focused on the work at hand.

I thank my fellow Directors for their collegiate working, generous sharing of knowledge, and team spirit in establishing CannPal from its inception, and wish the team all success for the future.”

This announcement has been approved and authorised to be given to the ASX by Mr Geoff Starr, the Chairman of CannPal Animal Therapeutics Limited.

ENDS

For further information, please contact:

CannPal Animal Therapeutics

Layton Mills

Managing Director

M: 0431 302 667

E: Layton@cannpal.com